Careful patient selection may improve response rates to infliximab in inflammatory bowel disease
Author:
Publisher
Wiley
Subject
Gastroenterology,Hepatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1440-1746.2006.04739.x/fullpdf
Reference24 articles.
1. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
2. The safety profile of infliximab in patients with Crohn’s disease: The Mayo Clinic experience in 500 patients
3. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy?
4. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County
5. Predictors of response to infliximab in luminal Crohn's disease
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Ethical Challenges Posed by Neurotechnology in Treating Disability;Highlights in Science, Engineering and Technology;2023-03-21
2. Refractory Proctitis;Biomarkers in Inflammatory Bowel Diseases;2019
3. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model;Health Technology Assessment;2016-05
4. Guidelines for Medical Treatment of Crohnʼs Perianal Fistulas;Inflammatory Bowel Diseases;2015-04
5. The importance of validating proposed genetic profiles in IBD;Journal of Internal Medicine;2014-01-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3